Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to $5,000.

  • Dianthus Therapeutics' Capital Expenditures fell 80.00% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $106,000, marking a year-over-year increase of 26.19%. This contributed to the annual value of $105,000 for FY2024, which is 4.55% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' Capital Expenditures stood at $5,000, which was down 89.13% from $46,000 recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Capital Expenditures peaked at $129,000 during Q2 2022, and registered a low of -$46,000 during Q3 2022.
  • Moreover, its 3-year median value for Capital Expenditures was $24,000 (2025), whereas its average is $26,364.
  • Within the past 5 years, the most significant YoY rise in Dianthus Therapeutics' Capital Expenditures was 241.30% (2023), while the steepest drop was 83.72% (2023).
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Capital Expenditures stood at $29,000 in 2022, then slumped by 65.52% to $10,000 in 2023, then skyrocketed by 210.00% to $31,000 in 2024, then slumped by 80.00% to $5,000 in 2025.
  • Its Capital Expenditures was $5,000 in Q3 2025, compared to $46,000 in Q2 2025 and $24,000 in Q1 2025.